IL2 and hepatocellular carcinoma: Towards the same direction, Tian et al. utilized Zol in combination with IL-2 in vitro, concluding that, in conjunction, they could expand circulating γδ T cells in HCC patients, enabling them to lyse HCC cells without raising immunosuppressive factors during amplification [80].